N ‐substituted phthalazine sulfonamide derivatives as non‐classical aldose reductase inhibitors
Journal of Molecular Recognition · 2022-12 · 35 (12)
DOI: 10.1002/jmr.2991 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Recognition, online erschienen am 26.09.2022. Verfasst von Cüneyt Türkeş und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Pharmacy, Erzincan Binali Yıldırım University, Erzincan, Turkey. Hauptthemen laut MEDLINE: Aldehyde Reductase, Enzyme Inhibitors. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 85 Literaturangaben.
Abstract (Originalsprache)
Aldose reductase (AR, AKR1B1; EC 1.1.1.21) is an aldo‐keto reductase that has been widely investigated as an enzyme crucially involved in the pathogenesis of several chronic complications, including nephropathy, neuropathy, retinopathy, and cataracts associated with diabetes mellitus. Although sulfonamides have been reported to possess many other biological activities, in continuation of our interest in designing and discovering potent inhibitors of AR, herein, we have evaluated the AR inhibitory potential of N ‐substituted phthalazine sulfonamide derivatives 5a‐l . The biological studies revealed that all the derivatives show excellent activity against AR, with K I constants ranging from 67.73 to 495.20 nM. Among these agents, 4‐(6‐nitro‐1,4‐dioxo‐1,2,3,4‐tetrahydrophthalazine‐2‐carbonyl)benzenesulfonamide ( 5e ) and 1,4‐dioxo‐3‐(4‐sulfamoylbenzoyl)‐1,2,3,4‐tetrahydrophthalazine‐6‐carboxylic acid ( 5f ) showed prominent inhibitory activity with K I values of 67.73 and 148.20 nM, respectively, vs AR and were found to be more potent than epalrestat ( K I = 852.50 nM), the only AR inhibitor currently used in the therapy. Moreover, molecular docking studies were also performed to rationalize binding site interactions of these sulfonamides ( 5a‐l ) with the target enzyme AR. According to ADME‐Tox, predicts were also determined that these derivatives be ARIs displaying suitable drug‐like properties. The sulfonamides identified in this study may be used to develop lead therapeutic agents inhibiting diabetic complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Faculty of Pharmacy, Erzincan Binali Yıldırım University, Erzincan, Turkey.
- Department of Chemistry, Faculty of Arts and Sciences, Sakarya University, Sakarya, Turkey.
- Department of Pharmacy Services, Nihat Delibalta Göle Vocational High School, Ardahan University, Ardahan, Turkey.
- Department of Chemistry, Faculty of Mathematical and Natural Sciences, Prishtina University, Republic of Kosova, Serbia.
- Department of Biochemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey.
- The Rectorate of Bilecik Şeyh Edebali University, Bilecik, Turkey.
ORCID-Profile: Cüneyt Türkeş, Mustafa Arslan, Yeliz Demir, Şükrü Beydemir
Zitieren
APA
Türkeş, C., Arslan, M., Demir, Y., Çoçaj, L., Nixha, A. R., & Beydemir, Ş. (2022). N ‐substituted phthalazine sulfonamide derivatives as non‐classical aldose reductase inhibitors. Journal of Molecular Recognition, 35(12). https://doi.org/10.1002/jmr.2991
Vancouver
Türkeş C, Arslan M, Demir Y, Çoçaj L, Nixha AR, Beydemir Ş. N ‐substituted phthalazine sulfonamide derivatives as non‐classical aldose reductase inhibitors. Journal of Molecular Recognition. 2022;35(12). doi:10.1002/jmr.2991
BibTeX
@article{Trke2022,
author = {Türkeş, Cüneyt and Arslan, Mustafa and Demir, Yeliz and Çoçaj, Liridon and Nixha, Arleta Rifati and Beydemir, Şükrü},
title = {N ‐substituted phthalazine sulfonamide derivatives as non‐classical aldose reductase inhibitors},
journal = {Journal of Molecular Recognition},
year = {2022},
volume = {35},
number = {12},
doi = {10.1002/jmr.2991}
}
EUVIMED